[ This article was originally published here ]RSAC 2023 was a huge success. We launched our , which was met with enthusiasm by the industry and the media. In fact, Will Townsend, , noted that our report joined other great research by industry peers who are striving to…
Source: www.cybersecurity-insiders.com – Read more
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
